Literature DB >> 17349883

Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years.

Stephen G Ellis1, Antonio Colombo, Eberhard Grube, Jeffrey Popma, Joerg Koglin, Keith D Dawkins, Gregg W Stone.   

Abstract

OBJECTIVES: This study sought to study stent thrombosis with the paclitaxel-eluting Taxus stent.
BACKGROUND: The incidence and timing of stent thrombosis after drug-eluting stent placement compared with bare-metal stent implantation remain unsettled, with consequent uncertainty about risk stratification and long-term recommendations for antiplatelet medications.
METHODS: This study used a patient-based meta-analysis using the 4 principal TAXUS randomized trials (3,445 patients) with a follow-up duration of > or =1 year.
RESULTS: Cumulative stent thrombosis occurred in 1.28% +/- 0.31% in the Taxus group and 0.76% +/- 0.23% in the bare-metal stent group at 3 years (hazard ratio 1.51 [95% confidence interval 0.73 to 3.14], p = 0.26). Hazard ratios (per 100 patients per 6 months) were similar between the Taxus stent group (0.59 [95% confidence interval 0.22 to 0.95]) and the bare-metal stent group (0.64 [95% confidence interval 0.26 to 1.02]) through 6 months during the prescribed clopidogrel period. However, from 6 months to 3 years there were more stent thromboses in the Taxus group (hazard ratio 0.19 [95% confidence interval 0.06 to 0.32] vs. 0.02 [95% confidence interval 0.00 to 0.07], p = 0.049). Of 8 patients with Taxus-related thrombosis after 6 months, 0 were taking clopidogrel and 2 were not taking aspirin consistently. No Taxus-related stent thrombosis occurred after 2 years (922 patients thus far followed up for 3 years). Independent correlates of stent thrombosis were nonuse of clopidogrel, male gender, smoking, and possibly use of multiple nonoverlapping stents.
CONCLUSIONS: Approximately 0.8% of Taxus patients have stent thrombosis in the first 6 months after stent implantation, similar to bare-metal stents. However, a modest increase in risk is present with Taxus stents beyond 6 months, possibly because of inadequate antiplatelet drug therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17349883     DOI: 10.1016/j.jacc.2007.01.015

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

Review 1.  Late stent thrombosis: the last remaining obstacle in coronary interventional therapy.

Authors:  Piera Capranzano; George Dangas
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

2.  The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I) : the one-year clinical follow-up.

Authors:  Martin Unverdorben; Ralf Degenhardt; Marcus Wiemer; Dieter Horstkotte; Henrik Schneider; Christoph Nienaber; Wolfgang Bocksch; Michael Gross; Michael Boxberger; Christian Vallbracht
Journal:  Clin Res Cardiol       Date:  2007-08-23       Impact factor: 5.460

3.  Late adverse events after drug-eluting stent implantation.

Authors:  David F Kong; Eric L Eisenstein; Robert Harrington
Journal:  Curr Cardiol Rep       Date:  2008-07       Impact factor: 2.931

4.  Endovascular treatment of the vertebral artery origin stenosis by using the closed-cell, self-expandable Carotid Wallstent.

Authors:  Jun-Kyeung Ko; Chang-Hwa Choi; Lee Hwangbo; Hie-Bum Suh; Tae-Hong Lee; Han-Jin Cho; Sang-Min Sung
Journal:  Interv Neuroradiol       Date:  2020-06-20       Impact factor: 1.610

5.  Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings.

Authors:  Kumaran Kolandaivelu; Rajesh Swaminathan; William J Gibson; Vijaya B Kolachalama; Kim-Lien Nguyen-Ehrenreich; Virginia L Giddings; Leslie Coleman; Gee K Wong; Elazer R Edelman
Journal:  Circulation       Date:  2011-03-21       Impact factor: 29.690

Review 6.  Emerging genomic applications in coronary artery disease.

Authors:  Samir B Damani; Eric J Topol
Journal:  JACC Cardiovasc Interv       Date:  2011-05       Impact factor: 11.195

7.  Very Late Stent Thrombosis due to Neointimal Rupture After Paclitaxel-Eluting Stent Implantation.

Authors:  Won Ju Kee; Myung Ho Jeong; Soo Young Jang; Min Goo Lee; Keun-Ho Park; Doo Sun Sim; Young Joon Hong; Ju Han Kim; Youngkeun Ahn; Jung Chaee Kang
Journal:  Korean Circ J       Date:  2011-12-31       Impact factor: 3.243

8.  Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?

Authors:  K Ibrahim; N Hass; S Kolschmann; R H Strasser; R C Braun-Dullaeus
Journal:  Clin Res Cardiol       Date:  2008-07-28       Impact factor: 5.460

9.  Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries.

Authors:  Ilia Fishbein; Ivan Alferiev; Marina Bakay; Stanley J Stachelek; Peter Sobolewski; Meizan Lai; Hoon Choi; I-W Chen; Robert J Levy
Journal:  Circulation       Date:  2008-04-14       Impact factor: 29.690

Review 10.  Applications of optical coherence tomography in cardiovascular medicine, Part 2.

Authors:  Joseph W Villard; Amit S Paranjape; Danielle A Victor; Marc D Feldman
Journal:  J Nucl Cardiol       Date:  2009-05-29       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.